Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Cardiokine
company
About
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of
- 11 - 50
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $37M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$87M
Cardiokine has raised a total of
$87M
in funding over 2 rounds. Their latest funding was raised on
May 1, 2006 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 1, 2006 | Series B | $50M | 1 | — | — | Detail |
| Apr 13, 2004 | Series A | $37M | 1 |
Perseus-Soros Biopharmaceutical Fund
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Cardiokine is funded by 1 investors.
Perseus-Soros Biopharmaceutical Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Perseus-Soros Biopharmaceutical Fund
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
